STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
NCT01167114
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
28
Enrollment
OTHER
Sponsor class
Conditions
Esophagogastric Cancer
Interventions
DRUG:
STA-9090
Sponsor
Massachusetts General Hospital
Collaborators
[object Object]
[object Object]
[object Object]